Autologous Cell Therapy Stocks
Customized regenerative medicine and oncology treatments utilize a patient’s own genetically modified or expanded immune cells to target specific diseases, creating a high-barrier therapeutic moat. These developers face unique commercialization hurdles including intensive logistical requirements for vein-to-vein transport and the capital-heavy nature of specialized manufacturing facilities.
As of Oct 23, 2026, Autologous Cell Therapy has 23 US-listed companies worth $19.8B combined. The median member moved +2.3% over the past week; RCEL led at +18.9% and INAB trailed at -5.4%.
Companies in Autologous Cell Therapy
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- LEGN – Legend Biotech Corp, $3.7B
- BEAM – Beam Therapeutics Inc, $2.5B
- VCEL – Vericel Corp Ord, $2.1B
- IMTX – Immatics NV, $1B
- IMMX – Immix Biopharma Inc, $803M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- PROK – ProKidney Corp., $695M
- AUTL – Autolus Therapeutics Ltd, $482M
- RCEL – Avita Medical Ltd, $404M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- ABEO – Abeona Therapeutics Inc, $252M
- RNAC – Cartesian Therapeutics Inc., $202M
- QNCX – Quince Therapeutics, Inc., $32.3M
- BCDA – Biocardia Inc, $15.7M
- INAB – In8bio Inc, $13.8M
- BLRX – BioLineRx Ltd, $11.7M
- BCLI – Brainstorm Cell Therapeutics Inc, $9.2M
- NKGN – NKGen Biotech, Inc. Common Stock, $7.8M
- ORGS – Orgenesis Inc, $3.4M
- BRTX – BioRestorative Therapies Inc, $3.1M
- MBIO – Mustang Bio Inc, $3.1M
- NEXI – Neximmune Inc, $139